Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its product candidate, OP-1250, is a novel oral therapy with combined activity as both a complete ER antagonist, or CERAN, and a selective ER degrader, or SERD, which is believed to drive deeper, more durable responses than existing therapies. The company was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Harmon Cyrus | Director | May 06 '24 | Sale | 10.92 | 5,000 | 54,600 | 806,283 | May 07 05:00 PM | Harmon Cyrus | Director | Apr 30 '24 | Sale | 9.51 | 15,000 | 142,650 | 811,283 | May 02 05:09 PM | Harmon Cyrus | Director | Mar 28 '24 | Sale | 10.97 | 20,000 | 219,400 | 826,283 | Mar 29 05:00 PM | Zojwalla Naseem | CHIEF MEDICAL OFFICER | Mar 18 '24 | Option Exercise | 4.87 | 13,700 | 66,719 | 80,364 | Mar 20 05:30 PM | Harmon Cyrus | Director | Feb 29 '24 | Sale | 12.41 | 25,000 | 310,309 | 846,283 | Mar 04 05:30 PM | Harmon Cyrus | Director | Feb 01 '24 | Sale | 15.56 | 5,000 | 77,800 | 871,283 | Feb 02 05:00 PM | Harmon Cyrus | Director | Jan 31 '24 | Sale | 12.23 | 25,000 | 305,750 | 876,283 | Feb 02 05:00 PM | Zojwalla Naseem | CHIEF MEDICAL OFFICER | Jan 25 '24 | Option Exercise | 7.02 | 20,000 | 140,400 | 66,664 | Jan 29 07:30 AM | Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OFF. | Jan 12 '24 | Option Exercise | 7.02 | 50,000 | 351,000 | 484,987 | Jan 16 07:30 AM | Harmon Cyrus | Director | Dec 29 '23 | Sale | 13.38 | 25,000 | 334,500 | 901,283 | Jan 02 05:30 PM | Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OFF. | Dec 12 '23 | Option Exercise | 7.02 | 10,000 | 70,200 | 434,987 | Dec 12 05:55 PM | Zojwalla Naseem | CHIEF MEDICAL OFFICER | Dec 11 '23 | Option Exercise | 7.02 | 2,900 | 20,358 | 46,664 | Dec 12 05:55 PM | Zojwalla Naseem | CHIEF MEDICAL OFFICER | Dec 06 '23 | Option Exercise | 7.02 | 13,100 | 91,962 | 43,764 | Dec 07 08:30 PM | Paradigm Biocapital Advisors L | 10% Owner | Dec 06 '23 | Buy | 11.60 | 100,000 | 1,160,000 | 6,590,981 | Dec 08 04:19 PM | Graham G. Walmsley | Director | Dec 05 '23 | Buy | 14.19 | 131,870 | 1,871,280 | 1,800,000 | Dec 18 06:30 PM | Harmon Cyrus | Director | Nov 30 '23 | Sale | 12.57 | 25,000 | 314,250 | 926,283 | Dec 01 05:15 PM | Bohen Sean | PRESIDENT AND CEO | Nov 22 '23 | Sale | 13.90 | 27,932 | 388,255 | 144,925 | Nov 22 07:00 PM | Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OFF. | Nov 22 '23 | Sale | 13.89 | 9,145 | 127,024 | 424,987 | Nov 22 07:00 PM | Zojwalla Naseem | CHIEF MEDICAL OFFICER | Nov 22 '23 | Sale | 13.89 | 7,095 | 98,550 | 30,664 | Nov 22 07:00 PM | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Nov 22 '23 | Sale | 13.89 | 6,653 | 92,410 | 574,099 | Nov 22 07:00 PM | Harmon Cyrus | Director | Nov 22 '23 | Sale | 13.90 | 3,989 | 55,447 | 951,283 | Nov 22 07:00 PM | Bohen Sean | PRESIDENT AND CEO | Nov 21 '23 | Sale | 14.88 | 29,293 | 435,879 | 172,857 | Nov 22 07:00 PM | Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OFF. | Nov 21 '23 | Sale | 14.86 | 9,597 | 142,632 | 434,132 | Nov 22 07:00 PM | Zojwalla Naseem | CHIEF MEDICAL OFFICER | Nov 21 '23 | Sale | 14.84 | 7,461 | 110,747 | 37,759 | Nov 22 07:00 PM | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Nov 21 '23 | Sale | 14.88 | 6,976 | 103,823 | 580,752 | Nov 22 07:00 PM | Harmon Cyrus | Director | Nov 21 '23 | Sale | 14.86 | 4,192 | 62,293 | 955,272 | Nov 22 07:00 PM | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Nov 08 '23 | Sale | 17.61 | 200 | 3,522 | 561,270 | Nov 13 05:30 PM | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Nov 03 '23 | Sale | 17.51 | 541 | 9,473 | 561,470 | Nov 03 09:39 PM | Harmon Cyrus | Director | Nov 02 '23 | Sale | 15.64 | 5,000 | 78,200 | 943,714 | Nov 02 08:50 PM | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Nov 02 '23 | Sale | 15.36 | 3,332 | 51,180 | 562,011 | Nov 03 09:39 PM | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Nov 01 '23 | Sale | 15.02 | 6,668 | 100,153 | 565,343 | Nov 03 09:39 PM | Harmon Cyrus | Director | Oct 31 '23 | Sale | 12.05 | 25,000 | 301,250 | 948,714 | Nov 02 08:50 PM | Harmon Cyrus | Director | Sep 29 '23 | Sale | 12.41 | 25,000 | 310,250 | 973,714 | Oct 03 05:00 PM | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Sep 19 '23 | Sale | 12.67 | 20,000 | 253,400 | 572,011 | Sep 21 05:00 PM | BVF PARTNERS L P/IL | Director | Sep 12 '23 | Buy | 9.84 | 1,505,932 | 14,818,371 | 4,688,954 | Sep 14 04:25 PM | Graham G. Walmsley | Director | Sep 12 '23 | Buy | 9.84 | 508,130 | 4,999,999 | 1,668,130 | Dec 18 06:30 PM | Harmon Cyrus | Director | Sep 05 '23 | Sale | 11.62 | 10,000 | 116,200 | 998,714 | Sep 05 09:08 PM | Harmon Cyrus | Director | Aug 31 '23 | Sale | 9.36 | 15,000 | 140,400 | 1,008,714 | Sep 05 09:08 PM | Harmon Cyrus | Director | Aug 16 '23 | Sale | 10.14 | 15,000 | 152,100 | 1,023,714 | Aug 17 05:00 PM | Harmon Cyrus | Director | Jun 08 '23 | Sale | 6.30 | 10,000 | 63,000 | 1,038,714 | Jun 09 05:30 PM | Harmon Cyrus | Director | Jun 06 '23 | Sale | 6.29 | 5,000 | 31,475 | 1,048,714 | Jun 07 09:30 PM | Harmon Cyrus | Director | Jun 05 '23 | Sale | 6.04 | 5,000 | 30,225 | 1,053,714 | Jun 07 09:30 PM |
|